Presidential Advisory From the AHA: Call to Action for Cardiovascular Disease in Women
The AHA has issued a presidential advisory statement regarding sex-based disparities in care of patients with cardiovascular disease.
Cardiovascular Disease
Testosterone Therapy for Hypogonadism Not Tied to Increased CV Risk
For men with hypogonadism, testosterone therapy does not appear to increase short- to medium-term cardiovascular risk.
Evinacumab Cuts LDL-C in Children With Homozygous Familial Hypercholesterolemia
Evinacumab is a fully-human monoclonal antibody that binds to and blocks the function of angiopoietin-like 3
Survivors of Childhood Cancer More Likely to Be Undertreated for CVD
Adult survivors of childhood cancer are more likely to be undertreated for cardiovascular disease (CVD) risk factors.
Dry Powder Inhaler Containing Treprostinil Gets FDA Approval
Tyvaso DPI is a drug-device combination therapy that consists of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler.
Monitoring, Management, and Lipid Profiles in Systemic Inflammation in RA
Investigators conducted a retrospective cross-sectional study of 756 patients with RA and an electronic medical record of erythrocyte sedimentation rate seen at least 2 times at a minority-serving metropolitan outpatient rheumatology clinic.
Increasing Estrogen Concentrations Reduces Cholesterol Expansion With Crystallization
Investigators assessed the impact of estrogen and testosterone on cholesterol crystallization and volume expansion as they relate to atherosclerotic plaque rupture.
FCHL and FH Associated With Increased and Similar Coronary Artery Disease Risk
Researchers investigated the relationship between cardiovascular risk and the genetic architecture of familial combined hyperlipidemia.
High-Intensity Statin Recommended in Patients With Atherosclerotic Cardiovascular Disease and Comorbid Nondialysis Chronic Kidney Disease
A team of investigators assessed patterns of statin therapy prescribed to patients with atherosclerotic cardiovascular disease with comorbid nondialysis chronic kidney disease.
FDA to Review Wearable Furosemide Delivery System for Outpatient Use
Furoscix is a wearable, pre-programmed on-body furosemide delivery system for outpatient self-administration.
- Loading...
Loading...
Next post in Heart Failure
Loading... 
Loading...